S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:ANIP

ANI Pharmaceuticals Stock Forecast, Price & News

$41.00
+0.45 (+1.11%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.51
$41.90
50-Day Range
$39.55
$50.90
52-Week Range
$26.10
$60.23
Volume
162,752 shs
Average Volume
73,455 shs
Market Capitalization
$583.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.21
30 days | 90 days | 365 days | Advanced Chart
Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


ANI Pharmaceuticals logo

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Headlines

U.S. FTC approves ANI deal to buy Novitium, with conditions
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
369
Year Founded
N/A

Sales & Book Value

Annual Sales
$208.48 million
Cash Flow
$6.26 per share
Book Value
$15.83 per share

Profitability

Net Income
$-22.55 million
Pretax Margin
-12.98%

Debt

Price-To-Earnings

Miscellaneous

Free Float
10,894,000
Market Cap
$583.88 million
Optionable
Optionable

Company Calendar

Last Earnings
10/31/2021
Today
1/21/2022
Next Earnings (Estimated)
3/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.79 out of 5 stars

Medical Sector

45th out of 1,418 stocks

Pharmaceutical Preparations Industry

15th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.9 5 -4 -3 -2 -1 -












ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

Is ANI Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals
or view top-rated stocks.

How has ANI Pharmaceuticals' stock price been impacted by COVID-19?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has increased by 7.0% and is now trading at $41.00.
View which stocks have been most impacted by COVID-19
.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for ANI Pharmaceuticals
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Sunday, October, 31st. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.70 by $0.31. The specialty pharmaceutical company earned $52.06 million during the quarter, compared to analyst estimates of $50.30 million. ANI Pharmaceuticals had a negative net margin of 10.40% and a positive trailing twelve-month return on equity of 17.80%. During the same quarter in the prior year, the business posted $0.70 earnings per share.
View ANI Pharmaceuticals' earnings history
.

What price target have analysts set for ANIP?

2 analysts have issued twelve-month price targets for ANI Pharmaceuticals' shares. Their forecasts range from $65.00 to $70.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $67.50 in the next year. This suggests a possible upside of 64.6% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Nikhil Lalwani, President, Chief Executive Officer & Director
  • James G. Marken, Senior VP-Operations & Product Development
  • Stephen P. Carey, Chief Financial Officer, Secretary & VP
  • Shanmugam Muthusamy, Director & Head-Research & Development
  • Rob W. Schrepfer, SVP-New Business Development & Specialty Sales

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.66%), State of Alaska Department of Revenue (0.05%), Collective Family Office LLC (0.04%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own ANI Pharmaceuticals stock include Jeanne Thoma, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals
.

Which institutional investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd..
View insider buying and selling activity for ANI Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying ANI Pharmaceuticals stock?

ANIP stock was bought by a variety of institutional investors in the last quarter, including Collective Family Office LLC, Louisiana State Employees Retirement System, and State of Alaska Department of Revenue. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Jeanne Thoma, Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $41.00.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals has a market capitalization of $583.88 million and generates $208.48 million in revenue each year. The specialty pharmaceutical company earns $-22.55 million in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals employs 369 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

Where are ANI Pharmaceuticals' headquarters?

ANI Pharmaceuticals is headquartered at 210 Main Street West, Baudette MN, 56623.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at [email protected], or via fax at 218-634-3540.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.